glp-1 market news New news: a major ad-trust fight just hit the weight loss drug space. The Guardian reports Ozempic maker Novo Nordisk is suing a US rival over what it calls “materially Reality check: Unpacking the $150B

The states second-largest insurer, Point32Health (which includes Harvard Pilgrim Health Care and Tufts Health Plan) has said it has no plans to change its coverage of GLP-1s, although it, like Blue Cross, has racked up hundreds of millions of dollars in losses, much of it driven by soaring demand for obesity drugs

The injections took place as soon as the subjects reached 3 weeks of age and continued over the course of 5 months

The little blue pill was the first medication to go mainstream to help men with performance issues in the bedroom or wanted a little help with getting a fuller and more erect penis

PubMed Central , Circulation , vol

GLP-1 receptors have been identified in various tissues involved in cardiovascular regulation, including areas of the central nervous system that influence autonomic function